| Name | Title | Contact Details |
|---|
Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.
Arbor Pharmaceuticals is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
American Health Packaging is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.